Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup

Today, almost all the available birth control options are female contraceptives. The biotech company Contraline, however, claims that clinical trials for its non-hormone and retro male contraceptive have reached an important milestone.

A News release Published today, the Contraline has announced that its male contraception, named Adam, has proven to be effective and safe in its first human clinical examination for 24 months. Although their clinical results have not yet been published in a scientific journal, the company plans to publish additional information during the April 26 American Eurological Association (AUA) meeting.

Adam is a water soluble hydrogel that contains two tubes of the men who carry sperm from the testicles to the urinary tract-is a minor method. The implant blocked the semen when allowing semen and the contextine is marketing it as the opposite alternative to the future, long -term, condom and vasectmez.

“Our goal was to create a male contraceptive option for two years, to respond directly to consumers’ needs,” said Alexander Pastusak, chief medical officer of the Controline, in the notice. “These searches ensure that Adam, the water soluble hydrogel in our novel, can achieve the purpose of the purpose.

The milestone is based on the first human clinical trial based on two participants of Azospermia (any sperm in their semen) in 24 months. A Previous news publishingContracen claims that Adam has reduced the number of ongoing sperm from 99.8% to 100.0% within 30 days of replacement.

These results “Kevin Eisenfrates, co-founder and CEO of Controline, said at the time,” Our contraceptive is a step forward to transform the landscapes. “They suggest” it is possible to achieve the effectiveness of the same level as a long-acting female contraceptive as IUD. In the end, when I would like to become a ‘any brain’ for men when considering the options of contraception. ”Ides, or GutSmall female contraceptive devices who are seared in the uterus.

The recent news release said none of the participants reported Adverse eventsOr in the face of unexpected security concerns. Researchers conducted by clinical trials will continue to observe other participants in 12-, 15-, 18-, and 21-month signs through labs and home-sighted tests. Furthermore, the regulatory approval of the second phase of the Contraline study has been fully approved.

However, Zone Oatley, a professor at the school of molecular bioscience at Washington State University, mentions that Adam Implant is still not public data, and researchers still do not know the long -term effects of blocking Vasa Deferentia, as he said, as he said. GuardianThe Oatley further suggested that most men would prefer a contraceptive pill or patch than any surgery.

However, but, however, Data from 2017 to 2019 Shows that 10.4% of women from the age of 15 to 49 have used long-acting retro contraceptive, such as IUD or other contraceptive implants need the necessary methods. It is less than four points of 14%of the pill. If Adam is truly proven to be safe and effective, then probably a significant number of men will also choose the long -term effectiveness of injection rather than the short -term functionality of other contraceptives.